August 15, 2011 -- Beijing SL Pharmaceutical will invest 130 million RMB ($20 million) in a Canadian JV, which it will form with PnuVax, an Ontario startup. Beijing SL Pharma will own 85% of the new entity. PnuVax, which specializes in vaccine manufacturing processes, will own the rest. The JV’s initial focus will be on 23-valent pneumococcal polysaccharide vaccines (PPSVs) that are intended for the China market. More details....
Stock Symbol: (SHE: 002038)
